Key Dates

Related Announcements

• November 6, 2023 - Notice of Change to Award Budget for PAR-23-032, Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed. See NOFO NOT-AR-23-021.
• October 27, 2022 - Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed). See NOFO PAR-23-032.

"

Issued by

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

This notice informs applicants of a change to the Award Information section of PAR-23-032, Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed.

Section II. Award Information

Currently Reads:

Award budget

Budgets up to $300,000 total costs for the whole Phase I project and up to $2,000,000 total costs for the whole Phase II project may be requested. The total costs include direct, indirect, and fees.

Revised to Read (changes shown in italics):

Award Budget

Budgets up to $350,000 total costs for the whole Phase I project and up to $2,300,000 total costs for the whole Phase II project may be requested. The total costs include direct, indirect, and fees.

All other aspects of this PAR remain the same.

Inquiries

Please direct all inquiries to:

Xibin Wang, PhD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-451-3884
Email: [email protected]